baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC TUR.WAR.OP.END. GXE/ DE000HD6R5Q3 /

24/01/2025 15:46:14	Chg.-0.0100	Bid15:53:36	Ask15:53:36	Underlying	Strike price	Expiration date	Option type
0.3900EUR	-2.50%	0.3800 Bid Size: 80,000	0.3900 Ask Size: 80,000	Galapagos N.V.	18.774 -	31/12/2078	Call

Newsfile Corp 25/10/2024 Trundless Expands Focus on Ecuador as a Top 2024 Travel Spot for Nature and Culture

Newsfile Corp 06/09/2024 Metropolitan Touring Achieves Sustainability Benchmark with Carbon-Neutral Commitment

GlobeNewswire 27/08/2024 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy

GlobeNewswire 23/08/2024 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...

GlobeNewswire 22/08/2024 Inspirato Introduces “Inspirato Invited”

GlobeNewswire 20/08/2024 Galapagos receives transparency notification from FMR LLC

GlobeNewswire 01/08/2024 Galapagos reports half-year 2024 financial results and provides second quarter business update

GlobeNewswire 14/06/2024 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...

GlobeNewswire 30/05/2024 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...

GlobeNewswire 16/05/2024 Galapagos creates new subscription right plans

GlobeNewswire 15/05/2024 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...

GlobeNewswire 02/05/2024 Galapagos reports first quarter 2024 financial results

GlobeNewswire 30/04/2024 Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and E...

GlobeNewswire 04/04/2024 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...

GlobeNewswire 28/03/2024 Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

GlobeNewswire 26/03/2024 Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

GlobeNewswire 22/02/2024 Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Cl...

GlobeNewswire 22/02/2024 Galapagos announces full year 2023 results and outlook for 2024

GlobeNewswire 15/02/2024 Galapagos presents at EBMT-EHA annual meeting 2024

GlobeNewswire 05/02/2024 NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

GlobeNewswire 31/01/2024 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

GlobeNewswire 04/01/2024 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...

GlobeNewswire 03/01/2024 Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule dru...

GlobeNewswire 02/01/2024 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

UC TUR.WAR.OP.END. GXE/ DE000HD6R5Q3 /

If you wish to receive reply to your feedback, please provide your email address.